The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline.

[1]  J. Wedzicha,et al.  Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[2]  장윤희,et al.  Y. , 2003, Industrial and Labor Relations Terms.

[3]  H. Völzke,et al.  Static lung volumes and airway resistance reference values in healthy adults , 2013, Respirology.

[4]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[5]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[6]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[7]  T. To,et al.  Quantifying comorbidity in individuals with COPD: a population study , 2014, European Respiratory Journal.

[8]  Satoshi Konno,et al.  Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[9]  R. Cimaz,et al.  Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease. , 2012, Swiss medical weekly.

[10]  J. Stausberg,et al.  Datenqualität in der medizinischen Forschung: Leitlinie zum adaptiven Management von Datenqualität in Kohortenstudien und Registern , 2014 .

[11]  M. Elia,et al.  Bioelectrical impedance analysis-part II: utilization in clinical practice. , 2004, Clinical nutrition.

[12]  R. Holle,et al.  [Multimorbidity and successful aging: the population-based KORA-Age study]. , 2011, Zeitschrift fur Gerontologie und Geriatrie.

[13]  이화영.  X , 1960, Chinese Plants Names Index 2000-2009.

[14]  G. Viegi,et al.  Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.

[15]  H. Völzke,et al.  Impact of Different Definitions of Airflow Limitation on the Prevalence of Chronic Obstructive Pulmonary Disease in the General Population , 2010, Respiration.

[16]  G. Alagic,et al.  #p , 2019, Quantum Inf. Comput..

[17]  C. Vogelmeier,et al.  Einfluss systemischer Manifestationen und Komorbiditäten auf den klinischen Zustand und den Verlauf bei COPD: Eine Übersicht über die Kohortenstudie COSYCONET , 2010 .

[18]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[19]  Per Bakke,et al.  The GOLD Classification Has Not Advanced Understanding of COPD , 2004 .

[20]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[21]  R. Holle,et al.  Spirometric Reference Values for Advanced Age from a South German Population , 2012, Respiration.

[22]  Wilson Tam,et al.  A longitudinal study of serial BODE indices in predicting mortality and readmissions for COPD. , 2011, Respiratory medicine.

[23]  T. Ng,et al.  Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.

[24]  A. Mirrakhimov.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony , 2012, Cardiovascular Diabetology.

[25]  P. J. Barnes,et al.  Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.

[26]  B. Nordestgaard,et al.  Body Mass, Fat Free Body Mass and Prognosis in COPD Patients from a Random Population Sample. , 2005 .

[27]  Edwin K Silverman,et al.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. , 2013, The Lancet. Respiratory medicine.

[28]  H Völzke,et al.  Airflow limitation, lung volumes and systemic inflammation in a general population , 2011, European Respiratory Journal.

[29]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[30]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[31]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[32]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[33]  D. Mannino,et al.  Economic Burden of COPD in the Presence of Comorbidities , 2015, Chest.

[34]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity) , 1993, European Respiratory Journal.

[35]  H. Seidl,et al.  Multimorbidität und erfolgreiches Altern , 2011, Zeitschrift für Gerontologie und Geriatrie.

[36]  B. Celli,et al.  Pulmonary rehabilitation and the BODE index in COPD , 2005, European Respiratory Journal.

[37]  C. Vogelmeier,et al.  Einfluss systemischer Manifestationenund Komorbiditäten auf den klinischen Zustand und den Verlaufbei COPD , 2010 .

[38]  J. Wedzicha,et al.  The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. , 2012, Chest.

[39]  H. Kimura,et al.  Immunogenicity of inactivated seasonal influenza vaccine in adult and pediatric liver transplant recipients over two seasons , 2013, Microbiology and immunology.

[40]  H. Kauczor,et al.  Assessment of the relationship between morphological emphysema phenotype and corresponding pulmonary perfusion pattern on a segmental level , 2014, European Radiology.

[41]  Martijn A Spruit,et al.  Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[42]  J. Wedzicha,et al.  Controversies in treatment of chronic obstructive pulmonary disease , 2011, The Lancet.

[43]  P. Kardos,et al.  Empfehlungen der Deutschen Atemwegsliga zur Spirometrie , 2006 .

[44]  E. Wouters,et al.  Treating the systemic effects of chronic obstructive pulmonary disease. , 2011, Proceedings of the American Thoracic Society.

[45]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[46]  Thomas de Quincey.  [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[47]  J. Wrobel,et al.  Epidemiology and clinical impact of major comorbidities in patients with COPD , 2014, International journal of chronic obstructive pulmonary disease.

[48]  N. Anthonisen,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005 .

[49]  P. Bakke,et al.  Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.

[50]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[51]  B. Nordestgaard,et al.  Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. , 2006, American journal of respiratory and critical care medicine.

[52]  S. Spencer,et al.  Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. , 2007, Chest.

[53]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[54]  Christian Gieger,et al.  Telomere length in circulating leukocytes is associated with lung function and disease , 2013, European Respiratory Journal.

[55]  R Merget,et al.  Body plethysmography--its principles and clinical use. , 2011, Respiratory medicine.

[56]  P. Bakke,et al.  The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. , 2012, Respiratory medicine.

[57]  N. Choudry,et al.  Early Detection and Impaired Quality of Life in COPD GOLD Stage 0: A Pilot Study , 2007, COPD.

[58]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[59]  Andrea Benedetti,et al.  Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD , 2014, COPD.

[60]  U. John,et al.  Study of Health in Pomerania (SHIP): A health examination survey in an east German region: Objectives and design , 2005, Sozial- und Präventivmedizin.

[61]  D. Caillaud,et al.  Impact of comorbidities on COPD-specific health-related quality of life. , 2013, Respiratory medicine.

[62]  P. Bakke,et al.  Chronic Obstructive Pulmonary Disease Is Associated with Low Levels of Vitamin D , 2012, PloS one.

[63]  Patrice Diot,et al.  Comorbidities of COPD , 2013, European Respiratory Review.

[64]  Edwin K Silverman,et al.  CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. , 2015, Radiology.

[65]  W. Rathmann,et al.  Cohort profile: the study of health in Pomerania. , 2011, International journal of epidemiology.

[66]  R Holle,et al.  KORA - A Research Platform for Population Based Health Research , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[67]  Peter Gluchowski,et al.  F , 1934, The Herodotus Encyclopedia.

[68]  J. Hankinson,et al.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.

[69]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[70]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[71]  P. Calverley.  The GOLD classification has advanced understanding of COPD. , 2004, American journal of respiratory and critical care medicine.

[72]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[73]  J. Zhan.  Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study , 2015 .

[74]  Diane Podsiadlo,et al.  The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.

[75]  H. Magnussen,et al.  Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbidities. , 2009, Proceedings of the American Thoracic Society.

[76]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[77]  J. Leuppi,et al.  Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. , 2012, Swiss medical weekly.

[78]  J. Kessler,et al.  DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia , 2004, International journal of geriatric psychiatry.

[79]  E. Schoon,et al.  Osteoporosis in chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[80]  E. Wouters,et al.  Osteoporosis in chronic obstructive pulmonary disease , 2013, Expert review of respiratory medicine.

[81]  D. Mannino,et al.  Economic Burden of Chronic Obstructive Pulmonary Disease by Presence of Comorbidities , 2015 .